Equities Analysts Offer Predictions for NTLA FY2029 Earnings

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) - Stock analysts at William Blair issued their FY2029 earnings per share (EPS) estimates for Intellia Therapeutics in a research note issued on Thursday, February 27th. William Blair analyst M. Minter anticipates that the company will post earnings per share of $2.96 for the year. William Blair currently has a "Neutral" rating and a $14.00 price target on the stock. The consensus estimate for Intellia Therapeutics' current full-year earnings is ($5.07) per share.

Other equities research analysts also recently issued reports about the company. Oppenheimer decreased their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a report on Monday, January 13th. Citigroup raised their target price on shares of Intellia Therapeutics from $12.00 to $14.00 and gave the stock a "neutral" rating in a research note on Friday. StockNews.com raised shares of Intellia Therapeutics to a "sell" rating in a report on Friday, November 8th. Chardan Capital cut their price target on shares of Intellia Therapeutics from $91.00 to $68.00 and set a "buy" rating for the company in a report on Friday. Finally, Morgan Stanley lowered Intellia Therapeutics from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $56.00 to $11.00 in a report on Monday, January 27th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and an average target price of $42.12.

Intellia Therapeutics Stock Down 6.3 %

NTLA traded down $0.64 on Monday, hitting $9.45. 2,998,270 shares of the company traded hands, compared to its average volume of 3,289,680. The company has a 50 day moving average of $10.85 and a 200-day moving average of $15.55. Intellia Therapeutics has a 12-month low of $8.96 and a 12-month high of $33.28. The stock has a market capitalization of $962.47 million, a PE ratio of -1.74 and a beta of 1.80.

Insider Transactions at Intellia Therapeutics

In other Intellia Therapeutics news, CEO John M. Leonard sold 26,807 shares of the firm's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the completion of the transaction, the chief executive officer now directly owns 941,115 shares in the company, valued at approximately $11,462,780.70. This trade represents a 2.77 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders sold 29,000 shares of company stock valued at $352,551 in the last 90 days. 3.20% of the stock is currently owned by insiders.

Institutional Trading of Intellia Therapeutics

Several large investors have recently modified their holdings of NTLA. State Street Corp lifted its stake in Intellia Therapeutics by 17.9% in the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after buying an additional 780,754 shares in the last quarter. Hennion & Walsh Asset Management Inc. lifted its position in shares of Intellia Therapeutics by 125.2% in the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 120,997 shares of the company's stock valued at $1,411,000 after acquiring an additional 67,276 shares in the last quarter. Patient Square Capital LP acquired a new stake in shares of Intellia Therapeutics during the third quarter valued at $2,642,000. Charles Schwab Investment Management Inc. increased its position in Intellia Therapeutics by 4.8% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 827,545 shares of the company's stock worth $17,006,000 after purchasing an additional 37,714 shares in the last quarter. Finally, Avanza Fonder AB acquired a new position in Intellia Therapeutics in the 4th quarter valued at about $421,000. 88.77% of the stock is currently owned by institutional investors and hedge funds.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.